Pharm-Olam International

pharm-olam.com

Pharm-Olam International is a multi-national contract research organization (CRO) offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines. For further information about Pharm-Olam, please visit www.pharm-olam.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

PCI PHARMA SERVICES SELECTS THOUGHTWORKS FOR DIGITAL PLATFORM TRANSFORMATION WITH AGILE APPROACH

Thoughtworks | July 11, 2022

news image

Thoughtworks a global technology consultancy that integrates strategy, design and engineering to drive digital innovation, today announced the signing of a multi-year agreement with PCI Pharma Services, a leading global contract development and manufacturing organization. Thoughtworks will help PCI in its journey to digitize its supply chain, with the goal of accelerating the time it takes to bring clients’ life-changing therapies to market for patients. By co-developing too...

Read More

Business Insights

ANGELINI PHARMA, A NEW PARTNER IN EPILEPSY

Angelini Pharma | March 26, 2022

news image

On the occasion of Purple Day an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common one.1 The essential treatment goal of epilepsy the...

Read More

Business Insights

TFF PHARMACEUTICALS EXPANDS R&D OPERATIONS WITH NEW AUSTIN FACILITY

TFF Pharmaceuticals, Inc. | July 16, 2022

news image

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF’s total lab space, adding a dedicated lab for downs...

Read More

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

news image

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More
news image

Business Insights

PCI PHARMA SERVICES SELECTS THOUGHTWORKS FOR DIGITAL PLATFORM TRANSFORMATION WITH AGILE APPROACH

Thoughtworks | July 11, 2022

Thoughtworks a global technology consultancy that integrates strategy, design and engineering to drive digital innovation, today announced the signing of a multi-year agreement with PCI Pharma Services, a leading global contract development and manufacturing organization. Thoughtworks will help PCI in its journey to digitize its supply chain, with the goal of accelerating the time it takes to bring clients’ life-changing therapies to market for patients. By co-developing too...

Read More
news image

Business Insights

ANGELINI PHARMA, A NEW PARTNER IN EPILEPSY

Angelini Pharma | March 26, 2022

On the occasion of Purple Day an annual international event aimed at raising awareness of epilepsy, Angelini Pharma, international Italian pharmaceutical company, is committed to provide patients and healthcare professionals with innovative solutions improving the care of patients with epilepsy. Epilepsy is a common neurological disorder that typically results in seizures of various types, with focal seizures being the most common one.1 The essential treatment goal of epilepsy the...

Read More
news image

Business Insights

TFF PHARMACEUTICALS EXPANDS R&D OPERATIONS WITH NEW AUSTIN FACILITY

TFF Pharmaceuticals, Inc. | July 16, 2022

TFF Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced a significant expansion of its R&D operations through the lease of a new research and development facility located in Austin, Texas. The new facility of over 3,500 square feet significantly increases TFF’s total lab space, adding a dedicated lab for downs...

Read More
news image

Pharmacy Market

VALEMETOSTAT NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR TREATMENT OF PATIENTS WITH ADULT T-CELL LEUKEMIA/LYMPHOMA

Daiichi Sankyo | December 29, 2021

Daiichi Sankyo Company, Limited announced that it has submitted a New Drug Application to Japan’s Ministry of Health, Labour and Welfare for valemetostat, a potential first-in-class dual inhibitor of EZH1 and EZH2, for the treatment of patients with relapsed/refractory adult T-cell leukemia/lymphoma. ATL is a rare and aggressive type of peripheral T-cell lymphoma that occurs with greater frequency in parts of Japan and other regions.1,2 Patients with ATL face a poor prognosi...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us